Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Koh, Youngil | - |
dc.contributor.author | Bang, Soo-Mee | - |
dc.contributor.author | Lee, Jae Hoon | - |
dc.contributor.author | Yoon, Hwi-Joong | - |
dc.contributor.author | Do, Young-Rok | - |
dc.contributor.author | Ryoo, Hun-Mo | - |
dc.contributor.author | Lee, Nari | - |
dc.contributor.author | Kim, Seok Jin | - |
dc.contributor.author | Kim, Kihyun | - |
dc.contributor.author | Yoon, Sung-Soo | - |
dc.contributor.author | Won, Jong-Ho | - |
dc.contributor.author | Mun, Yeung-Chul | - |
dc.contributor.author | Lee, Moon-Hee | - |
dc.contributor.author | Rhee, Ki-Hyun | - |
dc.contributor.author | Kim, Hyo-Jung | - |
dc.contributor.author | Eom, HyeonSeok | - |
dc.contributor.author | Kim, Min Kyoung | - |
dc.contributor.author | Shin, Hyun Chun | - |
dc.date.accessioned | 2021-08-12T07:25:03Z | - |
dc.date.available | 2021-08-12T07:25:03Z | - |
dc.date.issued | 2010-02 | - |
dc.identifier.issn | 0939-5555 | - |
dc.identifier.issn | 1432-0584 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/18063 | - |
dc.description.abstract | The frequency of thromboembolic events (TE) in Caucasian patients with multiple myeloma (MM) receiving thalidomide as the initial treatment has been reported to be 10 similar to 58% without prophylactic anticoagulation. Korean MM patients treated with thalidomide were studied to determine the frequency of TE and associated risk factors. A retrospective medical record review of the Korean MM registry from 25 centers in Korea between 2003 and 2007 was performed. We assessed the incidence of arterial and venous TE and the associated clinical parameters. Three hundred and sixty MM patients (median age 61 years, range 32-88 years) received thalidomide treatment. Fourteen patients (3.9%) developed TE: 12 had venous and two had arterial locations. The sites for the venous TE included lungs (seven), lower extremities (four), upper extremities (one), and neck (one). Arterial TE developed in cerebral and peripheral arteries each. No single clinical parameter such as prerequisite for the metabolic syndrome, disease status, and treatment regimen were predictive for the development of TE. The frequency of TE in patients who received thalidomide as initial therapy (7/155) was not different from those who received thalidomide for progressive or relapsed disease (7/205, p = 0.592). The frequency of TE during thalidomide treatment in Korean patients with MM was low. No significant clinical factor was found to be a risk factor. The subgroup requiring thromboprophylaxis among the Korean patients with MM, receiving thalidomide, needs to be clarified. | - |
dc.format.extent | 6 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Springer Verlag | - |
dc.title | Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1007/s00277-009-0807-6 | - |
dc.identifier.wosid | 000273030800013 | - |
dc.identifier.bibliographicCitation | Annals of Hematology, v.89, no.2, pp 201 - 206 | - |
dc.citation.title | Annals of Hematology | - |
dc.citation.volume | 89 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 201 | - |
dc.citation.endPage | 206 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.subject.keywordPlus | DEEP-VEIN THROMBOSIS | - |
dc.subject.keywordPlus | VENOUS THROMBOEMBOLISM | - |
dc.subject.keywordPlus | PROGNOSTIC-FACTORS | - |
dc.subject.keywordPlus | RISK-FACTORS | - |
dc.subject.keywordPlus | DEXAMETHASONE | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | PREVENTION | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | POPULATION | - |
dc.subject.keywordPlus | EVENTS | - |
dc.subject.keywordAuthor | Multiple myeloma | - |
dc.subject.keywordAuthor | Thalidomide | - |
dc.subject.keywordAuthor | Thromboembolism | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.